CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

oleclumab

mAbexperimental

Oleclumab is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers. — Wikipedia

Clinical trial activity

25 trials · 25 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
20
Phase 3
1
Phase 4
0

Earliest trial started Jul 24, 2015 (NCT02503774)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • medi9447

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07146230Phase 2Sep 30, 2025AstraZeneca, Yeshiva University
NCT06606847Phase 2Sep 24, 2024AstraZeneca
NCT06060405Phase 2Oct 30, 2023University of Toronto
NCT05221840Phase 3Feb 7, 2022AstraZeneca, Institut Gustave Roussy
NCT05061550Phase 2Dec 20, 2021AstraZeneca, Parexel, University of Texas at Houston
NCT04940286Phase 2Sep 28, 2021University of Texas at Houston
NCT04668300Phase 2Dec 3, 2020National Cancer Institute (NCI), University of Texas at Houston
NCT04262375Phase 2Mar 2, 2020AstraZeneca, University of Toronto
NCT04262388Phase 2Mar 2, 2020AstraZeneca, University of Toronto
NCT04261075Phase 1Feb 17, 2020MedImmune
NCT04089553Phase 2Aug 29, 2019AstraZeneca, Columbia University
NCT03875573Phase 2Jun 15, 2019AstraZeneca, Curie Institute, Free University of Brussels
NCT03833440Phase 2Mar 31, 2019Aix-University of Marseille
NCT03794544Phase 2Mar 8, 2019MedImmune
NCT03773666Phase 1Feb 20, 2019AstraZeneca, Harvard University
NCT03819465Phase 1Dec 27, 2018AstraZeneca, University of California, San Diego
NCT03742102Phase 1/Phase 2 (Phase 2)Dec 21, 2018AstraZeneca, University of London
NCT03822351Phase 2Dec 19, 2018MedImmune
NCT03736473Phase 1Nov 7, 2018AstraZeneca
NCT03616886Phase 1/Phase 2 (Phase 2)Oct 31, 2018AstraZeneca, Free University of Brussels
Showing 20 of 25 trials
Page 1 / 2

Organizations

Research & Development (25)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit14832017
MedImmuneFor profit6622015
University of Texas at HoustonAcademic/Hospital4212017
University of TorontoAcademic/Hospital4312018
Free University of BrusselsAcademic/Hospital2212018
Aix-University of MarseilleAcademic/Hospital1112019
Australia New Zealand Gynaecological Oncology GroupAcademic/Hospital1012018
Columbia UniversityAcademic/Hospital1012019
Cooperative Ovarian Cancer Group for Immunotherapy NetworkAcademic/Hospital1012018
Curie InstituteAcademic/Hospital1012019
European Network for Gynaecological Oncological TrialAcademic/Hospital1012018
GCIG: Gynecologic Cancer InterGroupAcademic/Hospital1012018
Gynecologic Oncology Trial and Investigation Consortium, JapanAcademic/Hospital1012018
Harvard UniversityAcademic/Hospital1112019
Institut Gustave RoussyAcademic/Hospital1012022
Katholieke Universiteit LeuvenAcademic/Hospital1012018
Korean Gynecologic Oncology GroupAcademic/Hospital1012018
National Cancer Institute (NCI)Government1012020
Nordic Society for Gynaecologic OncologyAcademic/Hospital1112018
North Eastern Germany Society of Gynaecologic OncologyAcademic/Hospital1012018
25 organizations
Page 1 / 2